A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer

Trial Profile

A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2017

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DATA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Jun 2017 Status changed from completed to active, no longer recruiting.
    • 02 Jun 2017 Results (n=590) of analysis comparing the survival of women with chemotherapy-induced ovarian function failure with definite postmenopausal women and examining the influence of ovarian function recovery on survival, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 12 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top